3-Nitro-4-tert.-butyl-toluol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Nitro-4-tert.-butyl-toluol
• 英文别名: 1-Tert-butyl-4-methyl-2-nitrobenzene
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: NVVOPNMWKBRPAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-叔丁基甲苯 在 nitronium tetrafluoborate 作用下， 以 环丁砜 为溶剂， 生成 3-Nitro-4-tert.-butyl-toluol
  参考文献：
  名称：

  Aromatic Substitution. XX. Intact and Dealkylating Nitration of Propylated and Butylated Alkylbenzenes with Nitronium Tetronium Tetrafluoroborate

  摘要：

  DOI：

  10.1021/ja01060a020

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• CATALYTIC ESTER DECARBONYLATION
  申请人：Tolman William Baker

  公开号：US20160194276A1

  公开（公告）日：2016-07-07

  A process of preparing olefins of the formula (I) is described herein: with R 1 being a substituted or unsubstituted (C 1 -C 30 )hydrocarbyl, and R 2 being a substituted or unsubstituted (C 1 -C 20 )hydrocarbyl. The process includes reacting a compound of formula (II) wherein Ar is chosen from in the presence of a palladium-based catalyst and an organic solvent. A process of preparing olefins of the formula (III) is also described: with R 3 being a substituted or unsubstituted (C 1 -C 30 )hydrocarbyl, R 4 being a substituted or unsubstituted (C 1 -C 20 )hydrocarbyl, and R 5 being a substituted or unsubstituted (C 1 -C 30 ) hydrocarbyl. The process includes reacting a compound of formula (IV) wherein Ar is chosen from with a compound of formula (V) wherein Ar is chosen from in the presence of a palladium-based catalyst and an organic solvent.

  本文描述了一种制备具有化学式（I）的烯烃的过程： 其中R1是取代或未取代的（C1-C30）烃基，R2是取代或未取代的（C1-C20）烃基。该过程包括在钯基催化剂和有机溶剂的存在下，反应具有化学式（II）的化合物 其中Ar选择自 。还描述了一种制备具有化学式（III）的烯烃的过程： 其中R3是取代或未取代的（C1-C30）烃基，R4是取代或未取代的（C1-C20）烃基，R5是取代或未取代的（C1-C30）烃基。该过程包括在钯基催化剂和有机溶剂的存在下，反应具有化学式（IV）的化合物 其中Ar选择自 与具有化学式（V）的化合物 其中Ar选择自 。
• MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
  申请人：Sheth Urvi

  公开号：US20120309758A1

  公开（公告）日：2012-12-06

  The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

  本发明涉及调节ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节蛋白，以及相关的组合物和方法。本发明还涉及使用这些调节剂治疗ABC转运蛋白介导的疾病的方法。
• Luciferin Derivatives from Bicyclic Reactants and Aminothiol Derivatives and Methods of Use Thereof
  申请人：The Regents of the University of California

  公开号：US20130287699A1

  公开（公告）日：2013-10-31

  The present disclosure features a condensation reaction and a luciferin-unmasking reaction that can be carried out under physiological conditions. In general, the condensation reaction involves reacting a bicyclic reactant with an aminothiol derivative, generating a luciferin or luciferin derivative. A luciferin can provide detectable luminescence. A luciferin derivative can be unmasked to provide detectable luminescence in a luciferin-unmasking reaction. The present disclosure provides bicyclic reactants and aminothiol derivatives suitable for use in the condensation reaction. The condensation and luciferin-unmasking reactions find use in a variety of applications, which are also provided.

  本公开涉及一种可以在生理条件下进行的缩合反应和发光素暴露反应。通常，缩合反应涉及将双环反应物与氨基硫醇衍生物反应，生成发光素或发光素衍生物。发光素可以提供可检测的发光。发光素衍生物可以在发光素暴露反应中被揭示出来，提供可检测的发光。本公开提供适用于缩合反应的双环反应物和氨基硫醇衍生物。缩合和发光素暴露反应在各种应用中有用，这些应用也被提供。